Cytosin-Arabinosid

AML With Mutated NPM1

Shen yangPhase 3Active

B

63/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 81/ 100

Competitive context

13 Active assets in the AML With Mutated NPM1 cohort.

Asset / Sponsor	Phase	Rating
Azacitidine Shen yang	Phase 2	B
Daunorubicin Shen yang	Phase 2	B
Venetoclax Kura Oncology, Inc.	Phase 2	B
Arsenic Trioxide The University of Hong Kong	Phase 2	CCC
BN104 Institut de Recherches Internationales Servier (I.R.I.S.)	Phase 1/2	CC

View all 14 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant

A

Indicative ·

82 / 100

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.